Skip to main content

Peer Review reports

From: PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Original Submission
19 Aug 2019 Submitted Original manuscript
16 Oct 2019 Author responded Author comments - Hannah Buckley
Resubmission - Version 2
16 Oct 2019 Submitted Manuscript version 2
Publishing
18 Oct 2019 Editorially accepted
14 Nov 2019 Article published 10.1186/s12885-019-6273-1

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us